Skip to content

Clinical trials

Obesity trials in China with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Obesity Phase: Not applicable Country / region: China Clear all

195 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20101
20114
20123
20149
20156
20164
20172
20188
201914
20207
202119
202218
202315
202429
202529
202627

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed81
Unknown status47
Recruiting34
Not yet recruiting19
Active, not recruiting9
Terminated3
Enrolling by invitation1
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Peking University8
Wecare Probiotics Co., Ltd.8
Capital Medical University6
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School6
Chinese Academy of Sciences5
Nanfang Hospital, Southern Medical University5
Peking University Third Hospital5
China-Japan Friendship Hospital4
RenJi Hospital4
Second Affiliated Hospital, Zhejiang University, School of Medicine4

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Obesity195
Overweight75
Diabetes Mellitus, Type 214
Weight Loss14
Prediabetic State9
Polycystic Ovary Syndrome6
Diabetes Mellitus5
Hypertension5
Insulin Resistance5
Metabolic Syndrome5

Trials

Showing 1 to 25 of 195. Each trial links to its page on Pharma Observatory.

95 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.